Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Ulcer Disease After Gastric Bypass, Marginal Ulcer, Perforated Marginal Ulcer, Acutely Perforated Marginal Ulcer
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Fresno, California

Conditions: Venous Wound Ulcers
Interventions: Sorbion Dressing; Device
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
Interventions: Enhanced Digital Care, Education; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 6 more

Conditions: Burns, Trauma, Venous Ulcers
Interventions: MIST Therapy, Standard of care; Device · Other
Lead sponsor: Celleration, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Ulcerative Colitis
Interventions: Etrozulimab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 38
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pressure Injury
Interventions: NeoThelium FT (HCT/P 361); Other
Lead sponsor: NuScience Medical Biologics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Bossier City, Louisiana • Rayville, Louisiana

Conditions: Diabetic Foot, Chronic Ulcer
Interventions: ActiGraft, Standard of Care; Device
Lead sponsor: RedDress Ltd.; Industry
Eligibility: 19 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 12
States / cities: Montgomery, Alabama • Los Angeles, California • San Francisco, California + 8 more

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Toenail Fungal Infection, Cellulitis, Pitted Keratolysis, Diabetic Foot Ulcer, Abscess
Interventions: Footwash; Combination Product
Lead sponsor: Data Collection Analysis Business Management; Other
Eligibility: Not listed
Enrollment: 5,000 participants
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Land O' Lakes, Florida

Conditions: Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions: Nivolumab; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more

Conditions: Pressure Ulcer
Interventions: Skin IQ™ MCM Coverlet, Pressure redistribution surface; Device · Other
Lead sponsor: Arjohuntleigh; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Oklahoma City, Oklahoma • Dallas, Texas • Charlottesville, Virginia

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Deucravacitinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Shreveport, Louisiana • Wyoming, Michigan • Jackson, Mississippi + 7 more

Conditions: Stage 1 Pressure Ulcer, Stage 2 Pressure Ulcer
Interventions: Intermittent electrical stimulation system (IES) treatment and turning patient every two hours, Turning population every two hours; Device · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Cleveland, Ohio

Conditions: Osteoarthritis
Interventions: LT-NS001, Naprosyn®; Drug
Lead sponsor: Logical Therapeutics; Industry
Eligibility: 45 Years to 80 Years
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 65
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more

Conditions: Ulcerative Colitis
Interventions: BBT-401-1S first and then Placebo, Placebo first and then BBT-401-1S; Drug
Lead sponsor: Bridge Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 11
States / cities: Sacramento, California • Ventura, California • Boca Raton, Florida + 8 more

Conditions: Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions: Riboflavin; Drug
Lead sponsor: Joseph B. Ciolino, MD; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Inflammatory Bowel Disease
Interventions: Breast Milk Sampling, Risankizumab; Procedure · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: Lower Extremity or Diabetic Foot Ulcers, Bacterial Infection
Interventions: Larval Debridement Therapy, Bedside Sharp Debridement; Device · Procedure
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Irritable Bowel Syndrome, Ulcerative Colitis, Inflammatory Bowel Disease
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 60 Years
Enrollment: 198 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Eustachian Tube Dysfunction, Middle Ear Barotrauma, Middle Ear Disease, Middle Ear; Injury, Pressure Injury, Ear Barotrauma
Interventions: Hyperbaric Compression Profile; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Sleepy Hollow, New York

Conditions: Wounds and Injuries, Wound Healing, Ulcer
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Foot Ulcers
Interventions: FGF-1 141; Drug
Lead sponsor: Phage Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Ulcerative Colitis
Interventions: Low Dose MT-1303, High Dose MT-1303, Placebo, MT-1303; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 22
States / cities: Chandler, Arizona • Los Angeles, California • Rancho Cucamonga, California + 18 more

Search by objective public record fields.

Perforated Marginal Ulcer After Gastric Bypass

Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements

Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

Split Thickness Donor Site Healing With MIST Study

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Chronic Pressure Ulcers

Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs

Characterization of CD Responders to Vedolizumab

A Subjective Observational Study of Patients Using Medicated Footbath/Footwash Treatment in Podiatry Care

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

The PROTECT 2 Study : Pressure Injury Treatment by Intermittent Electrical Stimulation: A Randomized, Controlled Trial

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

Efficacy and Safety of BBT-401-1S in Ulcerative Colitis

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

Phenotyping IBS: Perceptions and Modulations of Visceral Sensations

Effect of Total Compression Time and Rate (Slope) on Incidence of Symptomatic ETD and MEB: A Phase II Prospective Study.

The Molecular Anatomy of Oral Wound Healing

Safety Study of Topical Human FGF-1 for Wound Healing

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis